EUVIMEDEUVIMED entdecken
LeitlinieOpen Access

Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021

Agam K Rao, Jeremy Sobel, Kevin Chatham-Stephens, Carolina Luquez

MMWR. Recommendations and Reports · 07.05.2021 · 70 (2) · 1-30

DOI: 10.15585/mmwr.rr7002a1 ↗

Kurz gefasst

Leitlinie in der Zeitschrift MMWR. Recommendations and Reports, online erschienen am 07.05.2021. Verfasst von Agam K Rao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, CDC. Die Arbeit wurde bisher 206-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Botulism is a rare, neurotoxin-mediated, life-threatening disease characterized by flaccid descending paralysis that begins with cranial nerve palsies and might progress to extremity weakness and respiratory failure. Botulinum neurotoxin, which inhibits acetylcholine release at the neuromuscular junction, is produced by the anaerobic, gram-positive bacterium Clostridium botulinum and, rarely, by related species (C. baratii and C. butyricum). Exposure to the neurotoxin occurs through ingestion of toxin (foodborne botulism), bacterial colonization of a wound (wound botulism) or the intestines (infant botulism and adult intestinal colonization botulism), and high-concentration cosmetic or therapeutic injections of toxin (iatrogenic botulism). In addition, concerns have been raised about the possibility of a bioterrorism event involving toxin exposure through intentional contamination of food or drink or through aerosolization. Neurologic symptoms are similar regardless of exposure route. Treatment involves supportive care, intubation and mechanical ventilation when necessary, and administration of botulinum antitoxin. Certain neurological diseases (e.g., myasthenia gravis and Guillain-Barré syndrome) have signs and symptoms that overlap with botulism. Before the publication of these guidelines, no comprehensive clinical care guidelines existed for treating botulism. These evidence-based guidelines provide health care providers with recommended best practices for diagnosing, monitoring, and treating single cases or outbreaks of foodborne, wound, and inhalational botulism and were developed after a multiyear process involving several systematic reviews and expert input.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BotulismCenters for Disease Control and Prevention, U.S.Evidence-Based MedicineHumansUnited States

Autor:innen und Institutionen

  • Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, CDC.

Zitieren

APA

Rao, A. K., Sobel, J., Chatham-Stephens, K., & Luquez, C. (2021). Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021. MMWR. Recommendations and Reports, 70(2), 1-30. https://doi.org/10.15585/mmwr.rr7002a1

Vancouver

Rao AK, Sobel J, Chatham-Stephens K, Luquez C. Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021. MMWR. Recommendations and Reports. 2021;70(2):1-30. doi:10.15585/mmwr.rr7002a1

BibTeX
@article{Rao2021,
  author = {Rao, Agam K and Sobel, Jeremy and Chatham-Stephens, Kevin and Luquez, Carolina},
  title = {Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021},
  journal = {MMWR. Recommendations and Reports},
  year = {2021},
  volume = {70},
  number = {2},
  pages = {1--30},
  doi = {10.15585/mmwr.rr7002a1}
}
Kostenlos starten →